Veterinary Orthobiologics Market Size, Share & Trends Report

Veterinary Orthobiologics Market (2024 - 2030) Size, Share & Trends Analysis Report By Mode of Delivery (Intra-muscular/Intra-lesional, Intra-articular), By Product, By Animal, By Application, By End Use, By Region, And Segment Forecasts

Market Segmentation

Veterinary Orthobiologics Product Outlook (Revenue, USD Million, 2018 - 2030)
- Stem Cells
- Platelet-rich Plasma (PRP)
- Other Biologics
Veterinary Orthobiologics Animal Outlook (Revenue, USD Million, 2018 - 2030)
- Canine
- Equine
- Others
Veterinary Orthobiologics Application Outlook (Revenue, USD Million, 2018 - 2030)
- Osteoarthritis
- Degenerative Joint Disease
- Other Applications
Veterinary Orthobiologics Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
- Intra-muscular/Intra-lesional
- Intra-articular
- Others
Veterinary Orthobiologics End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Veterinary Hospitals
- Veterinary Clinics
- Others
Veterinary Orthobiologics Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - By Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Stem Cells
    - Platelet-Rich Plasma (PRP)
    - Other Biologics
  - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
    - Canine
    - Equine
    - Others
  - By Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Osteoarthritis
    - Degenerative Joint Disease
    - Other Applications
  - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
    - Intra-muscular/Intra-lesional
    - Intra-articular
    - Others
  - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Veterinary Clinics
    - Others
  - U.S.
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Canada
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Mexico
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
- Europe
  - By Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Stem Cells
    - Platelet-Rich Plasma (PRP)
    - Other Biologics
  - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
    - Canine
    - Equine
    - Others
  - By Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Osteoarthritis
    - Degenerative Joint Disease
    - Other Applications
  - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
    - Intra-muscular/Intra-lesional
    - Intra-articular
    - Others
  - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Veterinary Clinics
    - Others
  - UK
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Germany
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - France
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Italy
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Spain
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Denmark
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Sweden
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Norway
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Japan
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - India
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - China
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - South Korea
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Australia
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Veterinary Clinics
    - Others
  - Thailand
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
- Latin America
  - By Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Stem Cells
    - Platelet-Rich Plasma (PRP)
    - Other Biologics
  - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
    - Canine
    - Equine
    - Others
  - By Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Osteoarthritis
    - Degenerative Joint Disease
    - Other Applications
  - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
    - Intra-muscular/Intra-lesional
    - Intra-articular
    - Others
  - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Veterinary Clinics
    - Others
  - Brazil
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Argentina
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
- Middle East and Africa (MEA)
  - By Product Outlook (Revenue, USD Million, 2018 - 2030)
    - Stem Cells
    - Platelet-Rich Plasma (PRP)
    - Other Biologics
  - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
    - Canine
    - Equine
    - Others
  - By Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Osteoarthritis
    - Degenerative Joint Disease
    - Other Applications
  - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
    - Intra-muscular/Intra-lesional
    - Intra-articular
    - Others
  - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
    - Veterinary Hospitals
    - Veterinary Clinics
    - Others
  - South Africa
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Saudi Arabia
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - UAE
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others
  - Kuwait
    - By Product Outlook (Revenue, USD Million, 2018 - 2030)
      - Stem Cells
      - Platelet-Rich Plasma (PRP)
      - Other Biologics
    - By Animal Outlook (Revenue, USD Million, 2018 - 2030)
      - Canine
      - Equine
      - Others
    - By Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Osteoarthritis
      - Degenerative Joint Disease
      - Other Applications
    - By Mode of Delivery Outlook (Revenue, USD Million, 2018 - 2030)
      - Intra-muscular/Intra-lesional
      - Intra-articular
      - Others
    - By End Use Outlook (Revenue, USD Million, 2018 - 2030)
      - Veterinary Hospitals
      - Veterinary Clinics
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments